Rubedo is not a hair company. It is a Californian biotech built around one bet: that ageing tissue is held back by senescent cells, damaged cells that stop dividing but refuse to die and keep sending out inflammatory signals. It raised a $40 million Series A in April 2024, led by Khosla Ventures and Ahren Innovation Capital, and in November 2024 appointed Frederick Beddingfield, a former Allergan dermatology executive and founder of Sienna Biopharmaceuticals, as chief executive. RLS-1496 was first aimed at chronic inflammatory skin disease and skin ageing, and the hair programme came later, flagged as early as the company's September 2025 announcement of US regulatory clearance for a separate skin trial.

That is a team with real dermatology drug-development experience. It is not evidence about hair, and everything about RLS-1496 in hair loss so far comes from the company's own announcements.

The case for senescence in pattern hair loss is not Rubedo's invention. It rests on a small body of work on dermal papilla cells, the cluster of cells at the base of the follicle that tells the hair to grow, and it connects to the androgen biology in our piece on DHT and the follicle.

A 2013 PLoS ONE study from Taiwan pushed the idea further. Using cells from four men with frontal balding and four age-matched controls, it found balding cells senesced faster (average doubling time 56.3 hours against 32.5), and that adding DHT pushed non-balding frontal scalp cells towards senescence but did not do so in beard cells, and knocking down the androgen receptor weakened the effect. DHT also increased markers of DNA damage. One detail worth knowing: the rise in p16INK4a with DHT was not statistically significant on its own in frontal scalp cells, only when the receptor was overexpressed.

These are cell-culture findings from small numbers of donors. They show that dermal papilla cells from balding scalp look more senescent in a dish, and that androgens can push scalp cells that way. They do not show that senescent cells in a living scalp cause miniaturisation rather than accompany it, or that clearing them would restore growth. That step, from association to treatment, is the question RLS-1496 is built to answer.

Rubedo's announcement goes further than the evidence. It says androgenetic alopecia is driven by "the accumulation of senescent and stressed dermal papilla cells that actively suppress stem cells", and that existing therapies "target secondary hormonal causes" (minoxidil, worth noting, is not a hormonal drug). That is a company's framing of a hypothesis, and our hair growth cycle and androgenetic alopecia articles show how much more complicated the follicle's decline is.

RLS-1496 is described by Rubedo as a GPX4 modulator. GPX4 is an enzyme that acts as a cell's rust-proofing, neutralising damaging oxidised fats in cell membranes. When GPX4 is disabled, iron-driven lipid damage builds up and the cell dies by ferroptosis, a regulated form of cell death distinct from the better-known apoptosis. Rubedo's bet is that senescent cells depend on GPX4 more than healthy ones, so that modulating it tips them, and not their neighbours, into ferroptosis.

That dependency is not only Rubedo's claim. A 2026 paper from the MRC Laboratory of Medical Sciences and Imperial College London reached the same conclusion independently.

So the senescent-cell vulnerability has independent support: senescent cells may be dependent on GPX4 in a way that healthy cells are not. What Rubedo adds is a topical drug it calls a "SenoAdaptive" modulator, which it says does two things at once. In its own words it "sensitizes cells to ferroptosis" in senescent cells and, separately, induces a "redox-reset" through a "controlled hormetic response" in stressed neighbouring cells, acting via NRF2 pathways. The release does not say whether the compound inhibits GPX4 outright or binds it some other way, and to our knowledge no peer-reviewed paper describing the molecule has been published.

Here is the part the announcement doesn't mention. Two 2026 papers in Free Radical Biology and Medicine suggest ferroptosis is a driver of damage in balding follicles, not a tool for repairing them.

The second paper implicates ferroptosis as a key mechanism of DHT-induced injury to dermal papilla cells. It identifies hispidulin, a natural flavonoid, as an activator of a lysosomal iron channel called TRPML1, and reports that in a DHT-induced mouse model oral hispidulin promoted hair regeneration and restored anagen-phase follicle structure, with the benefit lost when TRPML1 was blocked or when ferroptosis was forced with erastin.

A third strand is older. In a 2013 Journal of Investigative Dermatology study, mice engineered to lack Gpx4 in skin epithelial cells developed thickened skin, inflammation around the follicles, misshapen follicles and patchy hair loss in their first weeks, with raised lipid peroxidation and COX-2. Most of the damage resolved by about five weeks and the coat stayed sparse; the COX-2 inhibitor celecoxib, given to nursing mothers, substantially improved the pups' skin. That is complete deletion in developing skin, very different from a partial topical modulator in adult scalp, so it is a reason for care and not a prediction.

None of this refutes RLS-1496. These are preclinical papers, in cells and mice, from academic groups with no stated connection to the company, and they describe ferroptosis in dermal papilla cells under a DHT challenge, a different setting from selectively clearing senescent cells. The NRF2 result even fits half of Rubedo's pitch, since the company says its drug works partly through NRF2 in stressed cells.

But the tension is real, and the hair trial has to resolve it. If ferroptosis is damaging dermal papilla cells in balding follicles, a drug that sensitises cells to ferroptosis has to be selective enough to hit only the harmful ones. Whether RLS-1496 manages that in a human scalp is, to our knowledge, not something anyone has shown.

Before the hair announcement, RLS-1496 was tested in human skin, and that is the closest thing to a safety and activity record we have. All of it is company-reported, and none of it involves a scalp.

A second, open-label study in actinic keratosis reported a 46% reduction in lesion count at four weeks with 1% cream in the first 18 of 24 participants, against 11% in an untreated control, with minimal local irritation. A trade report puts the Phase 1 at 44 participants and notes the absence of formal psoriasis severity scores and any quantified vehicle response. No per-arm numbers are given.

For hair, that gives early reassurance that topical RLS-1496 was tolerated for a month on skin. It cannot tell us whether the effect on skin cells applies to dermal papilla cells deep in the follicle, what happens with daily scalp use for six months or longer, or how much of the drug reaches the bloodstream. To our knowledge, no systemic exposure data have been published.

The September announcement is the only public hair data, and it is worth reading closely, because the claims are stronger than the numbers it discloses.

Taken apart, this is a six-day culture of human follicles challenged with DHT. Follicle shaft elongation in a dish is a recognised laboratory readout, but it is not hair regrowth on a head. The release does not say how many follicles or donors were used, which doses were tested, how large the effect was or how the finasteride arm was run, and it calls the result significant at two doses in one sentence and greater at all doses in the next.

The finasteride comparison deserves particular care. Finasteride blocks the enzyme that makes DHT from testosterone. If DHT is added to the culture directly, as the release describes, that step is bypassed, so finasteride is not an obvious positive control for the model. The release does not explain why it was used, and a "numerically greater trend" without numbers is not the same as outperforming a comparator. The company's own wording is more careful than at least one hair loss website's headline, which reads "matches or outperforms finasteride".

Two further claims come with no detail. The first is that "in preclinical animal studies, RLS-1496 also achieved approximately 32% greater hair regrowth versus vehicle", with no species, model, dose, duration or sample size. The second is that spatial transcriptomics on patient follicle biopsies showed senescence markers and signals "consistent with activation of the follicular regenerative cascade", described as "human clinical evidence", without saying whether the biopsies came from treated or untreated people. The release also describes RLS-1496 as having "demonstrated efficacy in clinical trials" in skin conditions, when the underlying studies were a one-month Phase 1 and an early Phase 1b/2a.

Rubedo says a clinical study in androgenetic alopecia will begin in October 2026, with initial data expected in the first half of 2027, led by David Pariser, Professor of Dermatology at Eastern Virginia Medical School. That is nearly everything disclosed. The release does not state the trial phase, the number of participants, whether there is a vehicle control, the primary endpoint, the duration, the strength or the route. The investigator quoted in the release, who called the preliminary data "scientifically intriguing and warranted clinical evaluation" in Practical Dermatology's report, is also the person running the study.

One inference, flagged as ours: with the study due to begin in October 2026 and initial data expected by mid-2027, the first reported dataset could arrive within roughly eight months of the announced start. Hair counts typically need months of treatment to separate from placebo, as the hair growth cycle article explains, so an early or small dataset is more likely to be a safety and signal-finding exercise than a definitive efficacy test. That is a normal first step in drug development, and it should be read as one.

When the first data arrives, a few questions will separate a meaningful result from a promotional one. Was there a vehicle control, and was it blinded? Was the primary endpoint a standard measure such as target-area hair count, reported as absolute hairs per square centimetre with a baseline and a spread, not a percentage? How did the result compare with the placebo response, which is often substantial in hair trials? Were scalp tolerability and systemic exposure reported?

And did the benefit last? That question matters more than usual here. If RLS-1496 works primarily by clearing aged cells, the durability of any benefit after dosing stops would be an especially interesting test of the proposed mechanism. A persistent benefit would support the idea that removing a pathological cell population can produce a lasting change; loss of benefit would suggest that ongoing treatment or another mechanism is involved. Either result would be informative, and neither exists yet.

There is a defensible idea here. Balding dermal papilla cells look more senescent in culture, androgens can push scalp cells that way, and independent researchers have shown senescent cells can be selectively vulnerable to GPX4 disruption. The company has put a topical compound into human skin, reported no serious adverse events over about a month, and is starting a hair trial. A related idea, targeting senescent cells in the follicular niche, is also behind AMP-303, and our article on fisetin and quercetin covers why the food-derived versions of this approach are a very different proposition.

What has not been shown is that RLS-1496 grows hair on a human scalp, that a ferroptosis-based mechanism is selective enough to avoid the damage 2026 papers link to ferroptosis in balding follicles, that its skin safety carries over to a scalp used daily for months, or that the six-day follicle result reflects more than a culture-dish effect. The announcement's numbers are not disclosed, so the finasteride comparison cannot be judged. The first-half-2027 data will be the first real test, and until it arrives RLS-1496 is a hypothesis with a good pedigree, not a result.

This article is provided for educational purposes and does not constitute medical or investment advice. RLS-1496 is an investigational compound not approved for any use by the FDA, MHRA, EMA, or any other regulatory body, and its safety and efficacy in hair loss have not been shown. AmpleLab products are unrelated to RLS-1496 and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.